From the Desk of Evan Yu: “Fluciclovine (Axumin®) PET/CT Imaging in Prostate Cancer: More Uses than Just for Recurrent Disease?”
Fluciclovine is a synthetic amino acid that is uptaken by amino acid transporters that are upregulated in many cancer cells, including prostate cancer.1 Fluciclovine is not metabolized or incorporated into newly synthesized proteins,2 and it is ideal for labeling with 18F for imaging purposes. A key advantage is that it has low renal excretion, which is optimal for imaging the pelvis. Sensitivity and specificity and of PET imaging with fluciclovine appear superior to choline in a direct comparative trial of patients in the biochemically recurrent prostate cancer disease state.3 However, a greater impact of an imaging agent can be measured when key treatment decisions are altered based on findings from that imaging modality.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.